| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
- case study
- Korea
- China
- private equity
- nda
- Japan Tobacco
- OTCBB
- LOTTE
- PEF
- Acquistion
- Letter of intent
- buyout
- securities
- acquisition
- LOI
- Confidential Agreement
- Malaysia
- M&A
- sk
- Korea M&A
- hong kong
- taiwan
- cgi korea
- CA
- Investment
- Bank
- capital gate
- Japan
- Merger
- China Construction Bank
- Today
- Total
Korea M&A Corporation
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellencefor External Drug Discovery (CEEDD..
SmithKline, Glaxo merger valued at $75 billion January 17, 2000 SmithKline Beecham and Glaxo Wellcome agreed to merge and form the world's biggest pharmaceutical company in a deal valued at $75.7 billion. Both companies are based in London. SmithKline's U.S. headquarters is in Philadelphia; Glaxo's is in North Carolina. Under the proposed agreement, SmithKline COO Jaun-Pierre Garnier will serves..